Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jo Shorthouse

London, U.K
Jo Shorthouse is features editor for Scrip Intelligence and manages the Scrip 100 publication. Jo has covered the biopharmaceutical industry and related service industries since 2008 when she edited Good Clinical Practice journal followed by Scrip Clinical Research. Before this, she worked at various publications covering topics such as chemical logistics, the advertising industry and the property market.
Advertisement
Set Alert for Articles By Jo Shorthouse

Latest From Jo Shorthouse

Sanofi's Libtayo Lands In EU With Skin Cancer Nod

Nine months after the US approval, the EU has followed suit and given a conditional approval for Sanofi and Regeneron’s IO Libtayo for a, so far, untreatable skin cancer.

Europe Approvals

Sarepta Shares Bounce As Pfizer’s DMD Gene Therapy Sparks Safety Concerns

Pfizer is forging ahead with a Phase III trial for its DMD therapy, even though Phase Ib data raised safety worries. Gene therapy rival Sarepta’s shares were up by 17% on the news.

Gene Therapy Rare Diseases

Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development

Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.

Business Strategies Commercial

Anxious Investors Relieved At Bayer’s Fresh Monsanto Litigation Strategy

Bayer has taken steps to address the concerns of its stockholders by pulling together a legal team for its ongoing US glyphosate litigation, and bringing on board Merck’s Vioxx lawyer.

Companies Legal Issues

Vesalius’s “Proven Investment Strategy” Reflected In Largest Fund Close To Date

European fund manager Vesalius has closed its third fund with €120m. Its managers believe their strategy of investing in maturing companies has been the key to attracting commitments, including from the European Investment Fund.

Europe Financing

AMAG Must Build Market For Approved Female Libido Drug To Avoid Addyi’s Fate

AMAG Pharmaceutical’s HSDD drug Vyleesi, has been approved by the FDA. But analysts warn it must build the market in women who may not be aware they have a condition if it is to fare better than Sprout’s Addyi.

Approvals Gynecology & Urology
See All
Advertisement
UsernamePublicRestriction

Register